507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
oleh: Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Andrea Pirzkall, Praveen Bommareddy, Isla Leslie, Francesca Aroldi, Pablo Nenclares, Tze Chan, Imran Saleem, Henry Castro
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.